Agreements reached under this partnership
Business alliance- 1
This research is investigator-initiated specified clinical research aimed at exploring the uptake of 18F-FBPA in deep-seated cancers.
- 2
This research will use 18F-FBPA PET to evaluate the tumor accumulation of boron-based drugs for BNCT in deep-seated cancers and examine the possibility of expanding BNCT indications in the future.
- 3
The Company will provide the raw materials (precursors) and reference standards required to synthesize 18F-FBPA for use in this research.
- 4
The Company will ensure appropriate quality control for these materials in accordance with applicable laws and regulations and this agreement.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact of entering into this agreement on the Company's results for the fiscal year ending March 2027 is expected to be minor.
| Item | Details |
|---|---|
| Name of alliance partner | School Corporation Fujita Gakuen, SUMITOMO HEAVY INDUSTRIES,LTD., Atransen Technologies Co., Ltd., 株式会社マイクロン |
| Type of alliance | Business alliance |
| Details of the alliance | This research is investigator-initiated specified clinical research aimed at exploring the uptake of 18F-FBPA in deep-seated cancers., This research will use 18F-FBPA PET to evaluate the tumor accumulation of boron-based drugs for BNCT in deep-seated cancers and examine the possibility of expanding BNCT indications in the future., The Company will provide the raw materials (precursors) and reference standards required to synthesize 18F-FBPA for use in this research., The Company will ensure appropriate quality control for these materials in accordance with applicable laws and regulations and this agreement. |
| Contract Date | 1 October 2026 |
| Impact on Business Performance | The impact of entering into this agreement on the Company's results for the fiscal year ending March 2027 is expected to be minor. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To evaluate the tumor accumulation of boron-based drugs for BNCT in deep-seated cancers and examine the possibility of expanding BNCT indications in the future.